<DOC>
	<DOCNO>NCT01394575</DOCNO>
	<brief_summary>This phase II study . In patient node-negative invasive breast cancer carcinoma situ treat breast conserving surgery , postoperative whole breast irradiation inversely intensity modulate radiotherapy simultaneous integrate boost technically feasible . The aim study evaluate radiation toxicity , cosmetic outcome local control rate single center</brief_summary>
	<brief_title>Whole Breast Irradiation With Intensity Modulated Radiotherapy Simultaneously Integrated Boost Early Stage Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group performance score﹤2 All patient age &gt; 18 year &lt; 70 year breast conserve surgery . On histological examination , tumor must DCIS invasive adenocarcinoma breast . Negative nodal status determine sentinel node biopsy , axillary dissection . Axillary staging require patient DCIS No evidence distant metastasis Gross disease may unifocal multifocal pathologic ( invasive and/or DCIS ) tumor size excise negative margins（＞2mm） Surgical treatment breast must lumpectomy . Reexcision surgical margin permit . The patient must consent study must sign approve consent form . Eastern Cooperative Oncology Group performance score≧2 Presence extensive intraductal component ( ductal carcinoma situ occupy &gt; 25 % primary invasive tumour present adjacent primary tumour ) .Suspicious microcalcifications , density , palpable abnormality ( ipsilateral contralateral breast ) unless biopsied found benign . Proven multicentric carcinoma ( invasive cancer DCIS ) one quadrant separate . Metastatic disease ( M1 ) Pregnancy lactate Surgical margin microscopically assess positive pathologic evaluation . Psychiatric addictive disorder preclude obtain inform consent adherence protocol . Collagen vascular disease , specifically dermatomyositis CPK level normal active skin rash , systemic lupus erythematosis , scleroderma . Prior breast thoracic RT condition . Previous concomitant malignancy except nonmelanoma skin cancer , carcinoma situ cervix , invasive carcinoma colon , thyroid , cervix , endometrium treat five year prior study entry . Synchronous chemotherapy target therapy permit . Refusal patient include study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>simultaneous integrate boost</keyword>
	<keyword>tumor bed</keyword>
	<keyword>IMRT</keyword>
</DOC>